MORROW GEORGE J 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Mar 15, 2024
Insider Transaction Report
Form 4
MORROW GEORGE J
Director
Transactions
- Sale
Common Stock
2024-03-14$139.42/sh−20,000$2,788,432→ 0 total - Exercise/Conversion
Common Stock
2024-03-14$39.79/sh+20,000$795,800→ 20,000 total - Exercise/Conversion
Common Stock
2024-03-14$39.79/sh+20,000$795,800→ 20,000 total - Sale
Common Stock
2024-03-14$139.41/sh−20,000$2,788,278→ 0 total - Exercise/Conversion
Non-Qualified Stock Option
2024-03-14$39.79/sh−20,000$795,800→ 20,000 totalExercise: $39.79Exp: 2025-09-30→ Common Stock (20,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option
2024-03-14$39.79/sh−20,000$795,800→ 0 totalExercise: $39.79Exp: 2025-09-30→ Common Stock (20,000 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.87 to $142.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Option granted September 30, 2015 and vests in 36 equal monthly installments.